The best GLP-1 programs if your BMI is 27 to 29 of 2026

FDA labels require BMI 30+ or BMI 27+ with a comorbidity. Most insurance won't approve GLP-1 for BMI 27-29 without documentation of comorbidities. These four programs are the cleanest paths if you're in this range.

What to know first

The 27-29 BMI window is the most asked-about category we see in patient questions. Insurance approval is borderline, manufacturer DTC pricing is the same as for higher-BMI patients and most telehealth programs do prescribe in this range with appropriate documentation. The question is which programs handle this professionally versus those that paper over the BMI question with a cash-pay compounded shortcut. We prefer the former: BMI 27-29 patients should still be evaluated as if they have a chronic metabolic condition that warrants real medical care.

What we considered

  • Will prescribe at BMI 27-29 with appropriate comorbidity documentation
  • Clinician quality (not just rubber-stamp approval)
  • Tells you plainly whether insurance is realistic for you
  • Cash-pay path predictability if insurance doesn't work

Some visit links earn us a commission.

Scores out of 10, equal-weighted across five dimensions. How we score

Top pick: Mochi Health

Form Health's obesity-medicine specialists are the most likely in the chart to document the comorbidity criteria (prediabetes, hypertension, dyslipidemia) that get a BMI 27-29 patient over the insurance prior-auth bar.

Other strong picks

Henry Meds logo
Henry MedsHenry Meds at $199 flat-rate compounded is the next-cheapest predictable cash-pay route, slightly more expensive than Mochi but with a different clinical model.
Starts From
$297/moincl. medication
Lock-In
Month-to-month
Score
8
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.